Literature DB >> 1783779

Alternate pathogenesis of systemic neoplasia in the bivalve mollusc Mytilus.

J D Moore1, R A Elston, A S Drum, M T Wilkinson.   

Abstract

The proliferative disease systemic neoplasia, also termed hemic neoplasia or disseminated sarcoma, was studied in four Puget Sound, Washington populations of the bay mussel (Mytilus sp.). Using flow cytometric measurement of DAPI-stained cells withdrawn from the hemolymph, DNA content frequency histograms were generated for 73 individuals affected by the disease. The cells manifesting systemic neoplasia were found to exist as either of two separate types, characterized by G0G1 phase nuclear DNA contents of either approximately 4.9 x haploid (pentaploid form) or approximately 3.8 x haploid (tetraploid form). The two disease forms were found to coexist in all four mussel populations sampled, with overall relative prevalences of 66% pentaploid form, 29% tetraploid form, and 5% exhibiting both disease forms simultaneously. These findings represent the first unequivocal demonstration of multiple cell types in a bivalve neoplasia. The two forms appear to represent separate pathogenetic processes rather than sequential stages of a single pathogenesis. Two cell cycling parameters associated with proliferative activity were employed to compare the alternate forms: (i) the percentage of cells assigned to the DNA Synthesis (S) phase of the neoplastic cell cycle, and (ii) the proportion of neoplastic cell mitotic figures in hemocytological preparations. Mean values for both parameters were significantly higher for mussels with the tetraploid form of the disease, suggesting a higher rate of proliferation relative to the pentaploid form. Qualitatively, cells of the tetraploid form contained slightly lower nuclear and cytoplasmic volumes compared to those of the pentaploid form. An observed wide variation in neoplastic cell nuclear size within either disease form may reflect the distribution of cells in the G0G1, S, and G2M phases of the cell cycle. Potential etiologic relationships between the two forms are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1783779     DOI: 10.1016/0022-2011(91)90067-z

Source DB:  PubMed          Journal:  J Invertebr Pathol        ISSN: 0022-2011            Impact factor:   2.841


  6 in total

1.  Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams.

Authors:  Michael J Metzger; Carol Reinisch; James Sherry; Stephen P Goff
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

Review 2.  A Sixth Modality of Infectious Disease: Contagious Cancer from Devils to Clams and Beyond.

Authors:  Michael J Metzger; Stephen P Goff
Journal:  PLoS Pathog       Date:  2016-10-27       Impact factor: 6.823

3.  Nuclear morphometry and ploidy of normal and neoplastic haemocytes in mussels.

Authors:  Francesca Carella; Gionata De Vico; Gabriel Landini
Journal:  PLoS One       Date:  2017-03-10       Impact factor: 3.240

4.  First description of a widespread Mytilus trossulus-derived bivalve transmissible cancer lineage in M. trossulus itself.

Authors:  Maria Skazina; Nelly Odintsova; Maria Maiorova; Angelina Ivanova; Risto Väinölä; Petr Strelkov
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

5.  Prevalence and polymorphism of a mussel transmissible cancer in Europe.

Authors:  Maurine Hammel; Alexis Simon; Christine Arbiol; Antonio Villalba; Erika A V Burioli; Jean-François Pépin; Jean-Baptiste Lamy; Abdellah Benabdelmouna; Ismael Bernard; Maryline Houssin; Guillaume M Charrière; Delphine Destoumieux-Garzon; John J Welch; Michael J Metzger; Nicolas Bierne
Journal:  Mol Ecol       Date:  2021-07-16       Impact factor: 6.185

6.  Widespread transmission of independent cancer lineages within multiple bivalve species.

Authors:  Michael J Metzger; Antonio Villalba; María J Carballal; David Iglesias; James Sherry; Carol Reinisch; Annette F Muttray; Susan A Baldwin; Stephen P Goff
Journal:  Nature       Date:  2016-06-22       Impact factor: 49.962

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.